Research Papers:

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers

Takayuki Iwamoto _, Toyomasa Katagiri, Naoki Niikura, Yuichiro Miyoshi, Mariko Kochi, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Masako Omori, Yutaka Tokuda, Toshiyoshi Fujiwara, Hiroyoshi Doihara, Balazs Gyorffy and Junji Matsuoka

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:26122-26128. https://doi.org/10.18632/oncotarget.15385

Metrics: PDF 1833 views  |   HTML 2379 views  |   ?  


Takayuki Iwamoto1,2, Toyomasa Katagiri3, Naoki Niikura4, Yuichiro Miyoshi1, Mariko Kochi1,2, Tomohiro Nogami1, Tadahiko Shien1, Takayuki Motoki1,2, Naruto Taira1, Masako Omori5, Yutaka Tokuda4, Toshiyoshi Fujiwara2, Hiroyoshi Doihara1, Balazs Gyorffy6,7, Junji Matsuoka1,2,8

1Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan

2Department of Gastroenterological Surgery, Okayama University Hospital, Okayama, Japan

3Division of Genome Medicine, Institute for Genome Research, Tokushima University, Tokushima, Japan

4Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Kanagawa, Japan

5Department of Pathology, Okayama University Hospital, Okayama, Japan

6MTA TTK Lendület Cancer Biomarker Research Group, Budapest, Hungary

72nd Department of Pediatrics, Semmelweis University, Budapest, Hungary

8Department of Palliative and Supportive Medicine, Okayama University Hospital, Okayama, Japan

Correspondence to:

Takayuki Iwamoto, email: [email protected]

Keywords: short-term hormone therapy, IHC Ki67, genomic marker, breast cancer

Received: June 29, 2016     Accepted: January 31, 2017     Published: February 16, 2017


Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers.

Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post-Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively).

Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed.

Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the naïve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15385